Gonadorelin

Gonadorelin is a synthetic GnRH analog that prompts the pituitary to release LH and FSH; it has established clinical use in infertility and prostate cancer, but the peptide community has essentially no captured reports of off-label use. Clinician guidance for research use points to a flat 200 mcg daily subcutaneous dose, with no consensus on timing or cycling. The main tradeoff is that the off-label evidence base is thinner than the discourse suggests—most exploratory indications, spanning metabolic to oncologic uses, have no posted results.

Gonadorelin

Research Evidence

Evidence shape

Gonadorelin sits in the highest evidence tier, with the strongest trials concentrated in prostate cancer and infertility—forty and twenty trials respectively. The registered landscape spans ninety-two indications across sixty-one distinct sponsors, yet only fourteen have posted results and just seven are blinded with results, while seventy-five are thin or exploratory and sixty-five sit in a single-trial long-tail. Most of those ninety-two uses have been studied, but not at scale.

Depthhow much
189 registered trials
83 completed · 37 with posted results · 53 recruiting / active · combined n=17396
Breadthhow many areas
92 indications mapped
14 with results · 75 thin / exploratory · 1 animal-only · 65 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
7 blinded with results · 61 distinct sponsors · AE rows aggregated from 25 trials · 65 linked publications on registered trials
Breadth and depth196 rows captured
Human
direct clinical signal
189
Animal
translational support
4
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Anecdotal side effects

Price

1
PeptidesSource
US
100 mg
$15.00
$0.15/mg
2
Liberty Peptides
US
10 mg
$51.20
$5.12/mg
3
MyOasis Labs
--
10 mg
$84.00
$8.4/mg
4
PureHealth Peptides
--
2 mg
$17.00
$8.5/mg
5
Genesis Peptides
US
5 mg
$44.00
$8.8/mg
6
Core Peptides
US
10 mg
$90.00
$9/mg

price offers can be sorted by column

1-6 of 16

Dosing & Protocol

How Gonadorelin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 83
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

83 completed trials identified; trial dosing not reliably extracted from registry data.

8 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
200 µg
200 µg
200 µg
Frequency
daily
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 200 µg daily subQ (1 source).

1 source
Anecdotal
Community-reported real-world use · n = 3
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Anecdotal reports primarily discuss Gonadorelin for HPG axis modulation, though specific dosing details are not available from collected community posts. Out of 3 reports, 33.3% indicated positive effects and 66.7% indicated negative effects.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for Gonadorelin, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.